[go: up one dir, main page]

BRPI0611350B8 - formulação, seus usos e seu processo de fabricação,e artigo de fabricação - Google Patents

formulação, seus usos e seu processo de fabricação,e artigo de fabricação

Info

Publication number
BRPI0611350B8
BRPI0611350B8 BRPI0611350A BRPI0611350A BRPI0611350B8 BR PI0611350 B8 BRPI0611350 B8 BR PI0611350B8 BR PI0611350 A BRPI0611350 A BR PI0611350A BR PI0611350 A BRPI0611350 A BR PI0611350A BR PI0611350 B8 BRPI0611350 B8 BR PI0611350B8
Authority
BR
Brazil
Prior art keywords
formulation
article
manufacture
manufacturing process
compound
Prior art date
Application number
BRPI0611350A
Other languages
English (en)
Inventor
Brian Dzíennik David
Lloyd Oren Peter
Louis Ternik Robert
Beth Edelman Tamara
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0611350(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0611350A2 publication Critical patent/BRPI0611350A2/pt
Publication of BRPI0611350B1 publication Critical patent/BRPI0611350B1/pt
Publication of BRPI0611350B8 publication Critical patent/BRPI0611350B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

formulação, processo para a fabricação de um composto, artigo de fabricação, e, método para fabricar um medicamento. uma formulação de um composto de fórmula (1) processo de fabricação e métodos de usá-lo, são apresentados.
BRPI0611350A 2005-06-10 2006-06-06 formulação, seus usos e seu processo de fabricação,e artigo de fabricação BRPI0611350B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10
US60/689,183 2005-06-10
PCT/US2006/021860 WO2006135605A2 (en) 2005-06-10 2006-06-06 Formulation of a thienopyridine platelet aggregation inhibitor

Publications (3)

Publication Number Publication Date
BRPI0611350A2 BRPI0611350A2 (pt) 2010-12-07
BRPI0611350B1 BRPI0611350B1 (pt) 2020-09-15
BRPI0611350B8 true BRPI0611350B8 (pt) 2021-05-25

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611350A BRPI0611350B8 (pt) 2005-06-10 2006-06-06 formulação, seus usos e seu processo de fabricação,e artigo de fabricação

Country Status (34)

Country Link
US (1) US20080176893A1 (pt)
EP (1) EP1896019B1 (pt)
JP (1) JP2008543755A (pt)
KR (2) KR20080008413A (pt)
CN (1) CN101193633B (pt)
AR (1) AR054283A1 (pt)
AT (1) ATE441413T1 (pt)
AU (1) AU2006258102B2 (pt)
BR (1) BRPI0611350B8 (pt)
CA (1) CA2611668C (pt)
CY (1) CY1109502T1 (pt)
DE (1) DE602006008942D1 (pt)
DK (1) DK1896019T3 (pt)
DO (1) DOP2006000126A (pt)
EA (1) EA011693B1 (pt)
EC (1) ECSP077984A (pt)
ES (1) ES2330373T3 (pt)
HR (1) HRP20090516T1 (pt)
IL (1) IL187830A0 (pt)
MA (1) MA29688B1 (pt)
MX (1) MX2007015431A (pt)
MY (1) MY151038A (pt)
NO (1) NO20076317L (pt)
NZ (1) NZ564003A (pt)
PE (1) PE20070320A1 (pt)
PL (1) PL1896019T3 (pt)
PT (1) PT1896019E (pt)
RS (1) RS51194B (pt)
SI (1) SI1896019T1 (pt)
TN (1) TNSN07466A1 (pt)
TW (1) TWI318571B (pt)
UA (1) UA91051C2 (pt)
WO (1) WO2006135605A2 (pt)
ZA (1) ZA200710697B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
BRPI0720248A2 (pt) * 2006-12-07 2013-12-31 Lilly Co Eli Artigo de fabricação de prasugrel
CA2672157C (en) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Method for producing solid preparation
CA2672154C (en) * 2006-12-07 2014-11-18 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved storage stability
CA2823981C (en) * 2006-12-07 2016-05-17 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
KR101506043B1 (ko) * 2006-12-07 2015-03-25 다이이찌 산쿄 가부시키가이샤 저치환도 히드록시프로필셀룰로오스를 함유하는 의약 조성물
EP2123656B1 (en) * 2007-03-02 2014-06-11 Daiichi Sankyo Company, Limited Process for production of prasugrel hydrochloride having high purity
SI2152078T1 (sl) 2007-04-27 2021-08-31 Cydex Pharmaceuticals, Inc. Formulacije, ki vsebujejo klopidogrel in sulfoalkilni eter ciklodekstrina in metode uporabe
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
EP2257556A1 (en) * 2008-02-06 2010-12-08 Helm AG Prasugrel salts with improved properties
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
PL2112155T3 (pl) 2008-04-25 2011-03-31 Sandoz Ag Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania
WO2010094471A1 (en) * 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
EP2722036A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral formulations of prasugrel
EP2722037A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Prasugrel formulations
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
EP1298132B1 (en) * 2000-07-06 2006-11-22 Sankyo Company, Limited Hydropyridine derivative acid addition salts
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
EP1653930B1 (en) * 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin

Also Published As

Publication number Publication date
WO2006135605A3 (en) 2007-04-12
CN101193633B (zh) 2011-12-14
WO2006135605A2 (en) 2006-12-21
ECSP077984A (es) 2008-01-23
JP2008543755A (ja) 2008-12-04
EP1896019B1 (en) 2009-09-02
TNSN07466A1 (en) 2009-03-17
CY1109502T1 (el) 2014-08-13
EP1896019A2 (en) 2008-03-12
UA91051C2 (ru) 2010-06-25
RS51194B (sr) 2010-10-31
IL187830A0 (en) 2008-04-13
TW200718420A (en) 2007-05-16
EA200702670A1 (ru) 2008-04-28
AU2006258102B2 (en) 2011-09-15
PL1896019T3 (pl) 2010-01-29
PT1896019E (pt) 2009-11-19
TWI318571B (en) 2009-12-21
MY151038A (en) 2014-03-31
CN101193633A (zh) 2008-06-04
MX2007015431A (es) 2008-02-21
NZ564003A (en) 2011-07-29
AR054283A1 (es) 2007-06-13
DOP2006000126A (es) 2006-12-15
ES2330373T3 (es) 2009-12-09
KR20080008413A (ko) 2008-01-23
ZA200710697B (en) 2009-08-26
ATE441413T1 (de) 2009-09-15
AU2006258102A1 (en) 2006-12-21
NO20076317L (no) 2008-02-29
DE602006008942D1 (en) 2009-10-15
MA29688B1 (fr) 2008-08-01
BRPI0611350B1 (pt) 2020-09-15
PE20070320A1 (es) 2007-05-12
HRP20090516T1 (hr) 2009-10-31
CA2611668A1 (en) 2006-12-21
EA011693B1 (ru) 2009-04-28
CA2611668C (en) 2013-10-15
KR20100076050A (ko) 2010-07-05
SI1896019T1 (sl) 2010-01-29
US20080176893A1 (en) 2008-07-24
HK1116422A1 (en) 2008-12-24
DK1896019T3 (da) 2009-10-26
BRPI0611350A2 (pt) 2010-12-07

Similar Documents

Publication Publication Date Title
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
BRPI0519674A2 (pt) sulfonil pirrolidinas, mÉtodo para produzir as mesmas e seu uso como drogas
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
SE0401762D0 (sv) Novel compounds
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
EA200900397A1 (ru) Новые соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат
BRPI0413151A (pt) derivados de amino propanol
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ATE536864T1 (de) Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung
SE0403085D0 (sv) Novel componds
SE0403086D0 (sv) Compounds

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF